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ABSTRACT 
We have prepared a set of heterocyclic benzimidazole derivatives bearing amidino 
substituents at C-5 of benzimidazole ring, by introducing various heterocyclic nuclei 
(pyridine, N-methyl-pyrrole or imidazole) at C-2, and evaluated their antitumor and antiviral 
activities. The most pronounced antiproliferative activity was shown with compounds 6 and 9,
having imidazolinylamidino-substituent. Interestingly, all compounds show remarkable 
selectivity towards breast cancer cell line MCF-7. The most distinct and selective antiviral 
activity towards Coxackieviruses and Echoviruses was observed with compounds having 
pyridine ring at C-2. Especially interesting was fairly strong activity of 4  and 8 toward 
adenoviruses, which could be considered as leads against adenoviral replication. 
* Manuscript
Keywords: Benzimidazoles, amidines, N-methylpyrrole, pyridine, imidazole, antiviral 
activity, antitumor activity 
INTRODUCTION 
The incorporation of an imidazole nucleus, a biologically accepted pharmacophore, in the 
benzimidazole molecule has made it a versatile heterocycle possessing wide spectrum of 
biological activity.? Moreover, benzimidazole derivatives are structural isosters of naturally 
occurring nucleotides, which allows them to interact easily with the biopolymers of the living 
systems. Therefore, numerous biological activities and functions have been described: 
antihelmintic,2 antifungal,3 antiallergic, antimicrobial,4, 5, 6 antiviral7 and antineoplastic 
activity.8   
Antiviral properties of various benzimidazole derivatives have been reported in a variety 
of studies using different virus strains, such as human cytomegalovirus (HCMV)9, human 
immunodeficiency virus?0, ??, and hepatitis B and C virus.?2,?3 Also, amidino-substitu ted 
benzimidazoles, such as bis(5-amidino-2-benzimidazolyl)methane (BABIM) showed ability 
to block respiratory syncytial (RS) virus induced cell fusion?4. In addition, introducing 
amidino moiety to benzimidazole ring was shown to possess potent antimicrobial?5,?6 and 
antiprotozoal activity.?7
Besides, as a lead structure benzimidazole has been already used as a part of a central 
scaffold in some metallo- and serine proteases inhibitors, because of its potential in H-
bonding and ? – ? stacking interactions with the imidazole ring of His residues essential for 
the activity of these enzymes.?8 Alternatively, aromatic amidine molecules have been widely 
studied as competitive inhibitors of the protease enzymes because amidine moieties bind to an 
aspartic acid residue in the specificity pocket adjacent to the active site of several serine 
proteases to produce competitive inhibitors.?9 Since proteases have been linked to several 
disease states, including thrombosis, inflammation, bronchoconstriction, as well as tumor 
growth and invasion, 20 they are rational targets for inhibition by drugs. We have already 
shown that several amidino-substituted benzimidazoles strongly inhibit dipeptidiyl peptidase 
III2?, while Young et al.22 showed inhibitory activity of various amidinobenzimidazoles 
towards several coagulation proteases.  
In spite of the abovementioned and although many new benzimidazole derivatives 
have been synthesized as potential antitumor agents (e.g. pyrrolo[?,2-a]benzimidazoles23,
various 2-substituted benzimidazoles7, 24, 25), there is very scarce recent literature data on 
antitumor and antiviral potentials of amidino-substituted benzimidazoles that should combine 
favorable structural properties of both amidino and benzimidazole moiety. Therefore, we have 
prepared a set of heterocyclic benzimidazole derivatives (Figure ?) bearing amidino 
substituents at position C-5 of benzimidazole ring, by introducing various heterocyclic nuclei 
at position C-2, such as pyridine, N-methyl-pyrrole or imidazole and evaluated their 
antiproliferative/antitumor, as well as antiviral activities.  
Figure ?.
2. RESULTS AND DISCUSSION 
2.?. Chemistry 
The synthetic pathway for preparation of the benzimidazoles is shown in Scheme ?.
Compounds ?-9 were synthesized by condensation of corresponding aldehydes, 4(5)-
imidazolecarboxaldehyde, ?-methyl-?H-pyrrole-2-carbaldehyde and pyridine-2-carbaldehyde, 
appropriate 4-N-amidino substituted o-phenylenediamines and p-benzoquinone in absolute 
ethanol (3? -9?%, respectively).26
The corresponding 4-N-amidino substituted o-phenylenediamines were synthesized 
starting from acetamidobenzonitrile which were nitrated at first place to afford 4-amino-3-
nitrobenzonitrile. The nitrile group was then converted into the imidate ester, using Pinner 
methode,27 and the imidate ester was used directly without characterization to make the 
desired 4-N-amidino substituted o-phenylenediamines by described method.28 Corresponding 
aldehydes were purchased from Aldrich and used without further purification. 
Scheme ?.
Biological results 
Antiproliferative activity. The tested compounds showed different antiproliferative effect on 
the presented panel cell lines (Table ? and Figure 2). The activity of compounds bearing 
amidino substituents at position C-5 varies with introducing different heterocyclic substituents 
at position C-2. For instance, all compounds having imidazole moiety (?, 2 and 3) showed in 
general modest antiproliferative activity and no cytotoxicity towards normal cells (WI 38). 
Interestingly, the compounds ? and 3 have already been described to have inhibitory 
properties towards dipeptidyl peptidase2?. Furthermore, replacement of imidazole moiety by 
heterocyclic substituents with one heteroatom (N-methyl-pyrrole and pyridine) resulted in 
much more pronounced activity, but also cytotoxicity to normal cells. For example, 
compounds 6 and 9 (Figure 2), both having imidazolinylamidino-substituent showed strong 
growth inhibitory and slight cytotoxic activity toward all cell lines, while N-
isopropylamidino-substituted compound 8 inhibited the growth of all but H 460 cells. 
Interestingly, all compounds in general show remarkable selectivity towards breast cancer cell 
line (MCF-7), which is the most evident for carboxamidino-substituted compound ? and N-
isopropylamidino-substituted compound 6 .
Similar apparent selectivity of bis-benzimidazoles to breast cancer cells has also been 
previously shown by Seaton et al29. The authors have investigated the antiproliferative activity 
of the methoxy and dimethylamine bis-benzimidazole derivatives against many tumor cell 
lines. Although these compounds are DNA minor groove binders, they do not act as classical 
topoisomerase I and II inhibitors and the authors presume that their activity could be a 
combination of various mechanisms. A series of ?-substituted-2-methyl-5-
nitrobenzimidazoles have also shown cell-growth inhibitory activity to breast cancer cell line 
MCF-7.30 Moreover, several compounds of benzimidazole class that have predominantly been 
utilized as antifungal and antihelminthic agents, such as Mebendazole,3? oncodazole and 
methyl-2-benzimidazolecarbamate (Carbendazim, FB642) have also been investigated as 
potential antitumor drugs. FB642 produced tumor growth inhibition of greater than 58% in 
five of the seven human xenograft models evaluated. Interestingly, the antitumor activity of 
FB642 against MCF-7 breast tumors in mice was among the highest for all tumor models 
studied and was also better than either paclitaxel or vinorelbine.  
Consequently, the observed selectivity towards breast cancer cells should be correlated 
to benzimidazole, not to amidine moiety. Although different modes of action of various 
benzimidazoles have been described in the literature (e.g. DNA groove binding, 
topoisomerase I or II inhibition, interactions with microtubules, inhibition of tumor helicases), 
selective growth inhibitory activity towards breast cancer cells, especially MCF-7 line has not 
been explained. Since MCF-7 cells are known estrogen-dependant breast cancer cell line, this 
selectivity could possibly be explained as antiestrogenic effect of benzimidazoles. This 
hypothesis should, however, be further confirmed.   
Table ? .
Figure 2 
Antiviral activity. Compounds ?–9 did not show any growth inhibitory activity against GMK 
cell line and were, as such suitable for further antiviral testing on this cell line (data not 
shown). However, at the highest concentration compounds 6 and 9 showed cytotoxicity to 
HeLa cell line that was also used for antiviral testing (Table ? and Figure ?).  
Similar to antiproliferative activity described above, it was again demonstrated that all 
compounds having imidazole moiety (?-3) showed very low or no antiviral activity against all 
tested viruses. Compound 5 moderately and selectively inhibited the growth of echovirus 7 
(EC50 = 23.2 μM), while 7  effectively inhibited the growth of both enteroviruses, i.e. 
coxsackievirus B5 (EC50 = ?.7 μM) and echovirus 7 (EC50 = 3.2 μM). Furthermore, 8
efficiently inhibited the growth of adenovirus 5 (EC50 = ?5.2 μM), coxsackievirus B5 (EC50 = 
2.7 μM) and echovirus 7 (EC50 = 0.33 μM), but very poorly herpesvirus ?. Compound 9
considerably inhibited the growth of coxsackievirus B5 (EC50 = 4.3 μM) and echovirus 7 (EC50
= 0.63 μM). These results clearly demonstrate that all compounds having pyridine ring at 
position C-2 of an amidino-substituted benzimidazole showed selective and marked inhibitory 
activity towards RNA replicating enteroviruses. On the other hand, although 6  and 9
demonstrated certain antiviral effect towards herpesvirus ? (EC50 = 28.5 μM and 56.7 μM, 
respectively), the EC50 concentrations were rather high and close to cytotoxic concentrations, 
so it was hard to discern between these effects. Interestingly, the most consistent antiviral 
activity was observed with compound 4 that has carboxamidine substitutent at C-5 and N-
methyl-pyrrol at C-2 against all four types of viruses (adenovirus 5; EC50 = 5.9 μM), 
herpesvirus ?; EC50 = 30 μM, coxsackievirus B5; EC50 = 3.5 μM and echovirus 7; EC50 = 5 
μM), while having no cytotoxic activity whatsoever. 
As already mentioned, many studies confirmed antiviral activity of diverse 
benzimidazole derivatives, mostly against hepatitis,?2,?3 herpes viruses,32 cytomegalovirus,9 as 
well as coxackieviruses.33,34 Our results also prove that novel modifications of 
amidinobenzimidazole molecules with the 2-pyridyl substituent at position C-2 could enrich 
their antiviral potentials and direct the synthetic research to novel antiviral lead molecules. 
Furthermore, to our knowledge there has been no data reported presenting antiviral activity 
against adenoviruses. Therefore, compounds 4 and 8 could be promising potential antiviral 
agents and should be considered as leads for further synthetic structural optimization. Still, 
further research on understanding of the molecular mechanism of the observed antiviral effect 
on both DNA replicating viruses (adenovirus and herpesvirus) and the RNA replicating 
enteroviruses (coxsackievirus and echovirus) is needed.  
Table 2. 
CONCLUSIONS 
We have prepared a set of heterocyclic benzimidazole derivatives bearing amidino 
substituents at C-5 of benzimidazole ring, by introducing various heterocyclic nuclei at C-2. 
The principal aim of this study was to evaluate these compounds for their cytostatic and 
antiviral activities. The presented results confirm that novel 2-substituted-5-amidino-
benzimidazoles have both antiviral and antitumor potentials. The imidazole moiety at position 
C-2 (?-3) strongly reduced both the antiproliferative and antiviral activity of benzimidazoles, 
while its replacement by heterocyclic substituents with one heteroatom (N-methyl-pyrrole and 
pyridine) resulted in much more pronounced activity. The most pronounced antiproliferative 
activity was shown with compounds 6 and 9, having imidazolinylamidino-substituent. 
Interestingly, all compounds show remarkable selectivity towards breast cancer cell line 
(MCF-7). The most distinct and selective antiviral activity towards RNA replicating 
enteroviruses was observed with all compounds having pyridine ring at position C-2 of 
benzimidazole, which could thus be considered for further development. In contrast, 
carboxamidino-substituted compound 4 showed prominent activity against all four types of 
viruses. Especially interesting was fairly strong inhibitory activity of 4 and 8 toward the 
replication of Adenovirus 5. Since there have been no data describing antiviral activity of 
benzimidazoles toward adenoviruses, these compounds could be considered as leads for 
further synthetic structural optimization for inhibition adenoviral replication. 
EXPERIMENTAL 
Chemistry 
Melting points were obtained on an Original Kofler Mikroheitztisch apparatus (Reichert, 
Wien) and are uncorrected. IR spectra were recorded on a Nicolet Magna 760 
spectrophotometer in KBr discs. The ?H and ?3C NMR spectra were recorded on a Varian 
Gemini 300 and 600 MHz, respectively. All NMR spectra were measured in DMSO-d6
solutions using TMS as an internal standard. Elemental analysis for carbon, hydrogen and 
nitrogen were performed on a Perkin-Elmer 2400 elemental analyzer. Where analyses are 
indicated only as symbols of elements, analytical results obtained are within 0.4 % of the 
theoretical value. Mass spectra were recorded by using electrospray ionization technique 
(ESI) on the Micromass Platform LCZ single quadropole mass spectrometer. All compounds 
were routinely checked by TLC with Merck silica gel 60F-254 glass plates. 
General procedure for synthesis of compounds ?-9: 
Solution of 4-N-amidino substituted o-phenylenediamines, corresponding aldehyde and p-
benzoquinone in equimolar amounts in absolute ethanol were refluxed for four hours. After 
reaction mixture was cooled to room temperature, diethylether was added and the crude 
product was filtered off. The crude product was suspended in mixture of ethanol - diethylether 
several times until the powder was analytically pure. 
2-(?H-Imidazol-4-yl)-?H-benzimidazole-5-carboxamidine hydrochloride (?)
From 4(5)-imidazolecarboxaldehyde (0.090g, 0.94mmol), 3,4-diaminobenzamidine (0.?75g, 
0.94mmol) and p-benzoquinone (0.?08g, ?.0mmol) in absolute ethanol (5ml) after refluxing 
for 4 h yielded 0.?08g, 4?.?%, mp 275-277ºC. MS m/z: 227.2 (M+?, -HCl); IR (cm-?): 3?53, 
3005, 277?, ?69?, ?432, ?605 ?560; ?H NMR (DMSO-d6) (δ /ppm): ?3.02 (bs, ?H, NH), 
?2.60 (bs, ?H, NH), 9.20 (bs, 4H, NH) 8.90-8.85 (m, 2H, H), 7.85 (d, 2H, J=8.2Hz, Harom)
7.53 (s, ?H, Harom); (Anal. Calcd for (C??H??ClN6): C 50.29, H 4.22, N 3?.99; Found: C 50.35, 
H 4.33, N 3?.59. 
2-(?H-Imidazol-4-yl)-N-isopropyl-?H-benzimidazole-5-carboxamidine hydrochloride (2) 
From 4(5)-imidazolecarboxaldehyde (0.200g, 2.?mmol), 3,4-diamino-N-
isopropylbenzamidine (0.476g, 2.?mmol) and p-benzoquinone (0.227g, 2.?mmol) in absolute 
ethanol (5ml) after refluxing for 4 h yielded yielded 0.585g, 9?%, mp 22?-222ºC. MS m/z:
269.2 (M+?, -HCl) ; IR (cm-?): 3??6, 2980, 2935, ?670, ?6??, ?56?; ?H NMR (DMSO-d6)
(δ /ppm): ?3.2 (bs, ?H, NH), ?2.8 (bs, ?H, NH), 9.47 (bs, ?H, NH), 9.35 (bs, ?H, NH), 8.97 
(bs, ?H, NH), 7.96-7.88 (m, 2H), 7.79-7.69 (bs, ?H, NH), 7.48 (s, ?H), 4.09-4.06 (m, ?H, 
CH(CH3)2, ?.28 (d, 6H, J=6.30 Hz) ; Anal. Calcd for (C?4H?7ClN6): C, 55.?7; H, 5.62; N, 
27.57; Found: C, 55.35; H, 5.49; N, 27.35.
5-(4,5-Dihydro-?H-imidazol-2-yl)-2-(?-H-imidazol-4-yl)-?H-benzimidazole 
hydrochloride (3)
From 4(5)-imidazolecarboxaldehyde (0.?00g, ?.0mmol), 4-(4,5-dihydro-?H-imidazol-2-yl)-
benzene-?,2-diamine (0.2?2g, ?.0mmol) and p-benzoquinone (0.?08g, ?.0mmol) in absolute 
ethanol (5ml) after refluxing for 4h yielded 0.09.g, 3?.2%, mp >290ºC. MS m/z: 253.2 (M+?, -
HCl); IR (cm-?):338?, 3?03, 2968, 2854, ?629, ?608, ?509; ?H NMR (DMSO-d6) (δ /ppm): 
?3.?0 (bs, ?H, NH), ?2.80 (bs, ?H, NH), ?0.47 (bs, 2H, NH), 8.?6-8.?3 (m, 2H, H), 7.86 (d, 
?H, J=8.4Hz, H), 7.72 (d, ?H, J=8.4Hz), 7.62 (s, ?H, H), 3.96 (s, 4H, CH2); Anal. Calcd for 
(C?3H?3ClN6): C 54.08, H 4.54, N 29.??; Found: C 54.35, H 4.23, N 29.49. 
2-(?-Methyl-?H-pyrrol-2-yl)-?H-benzimidazole-5-carboxamidine hydrochloride (4) 
From ?-methyl-?H-pyrrole-2-carbaldehyde (0.02?2g, 0.?9mmol), 3,4-diaminobenzamidine 
(0.034g, 0.?9mmol) and p-benzoquinone (0.02?g, 0.?9mmol) in absolute ethanol (5ml) after 
refluxing for 4h yielded 0.04?g, 77.4%, mp 205-207ºC. MS m/z: 239 (M+?, -HCl); IR (cm-?): 
3356, 3090, 299?, ?65?, ?609, ?562; ?H NMR (DMSO-d6) (δ /ppm): ?3.08 (bs, ?H, NH), 
9.23 (bs, 4H, NH), 8.?6 (s, ?H), 7.9?-7.79 (m, 2H), 7.66-7.6? (m, 3H), 3.8 (s, 3H, CH3); Anal. 
Calcd for (C?3H?4ClN5) C, 56.63; H, 5.?2; N, 25.40; Found: C, 56.54; H, 5.32; N, 25.33.
N-Isopropyl-2-(?-methyl-?H-pyrrol-2-yl)-?H-benzimidazole-5-carboxamidine 
hydrochloride (5) 
From ?-methyl-?H-pyrrole-2-carbaldehyde (0.?09g, ?.0mmol), 3,4-diamino-N-
isopropylbenzamidine (0.228g, ?.0mmol) and p-benzoquinone (0.?08g, ?.0mmol) in absolute 
ethanol (5ml) after refluxing for 4h yielded 0.?95g, 6?.3%, mp 2?2-2?3ºC. MS m/z: 282.3 
(M+?, -HCl); IR (cm-?): 3344, 3???, 2980, ?666, ?6?3, ?504; ?H NMR (DMSO-d6) (δ /ppm): 
?3.0? (bs, ?H, NH), 9.49 (bs, ?H, NH), 9.37 (bs, ?H, NH), 9.02 (bs, ?H, NH), 8.00-7.86 (m, 
3H), 7.66-7.64 (m, 2H), 7.50 (d, ?H, J=8.1 Hz), 4.?6-4.07 (m, ?H), 3.50 (s, 3H, CH3), ?.29 
(d, 6H, J= 6.36 Hz), ; ?3C NMR (DMSO-d6) (δ /ppm): ?63.03 (s), ?50.75 (s), ?43.06 (s), 
?32.53 (s), ?24.47 (s), ?22.50 (s), ?22.06 (d, 2C), ??8.24 (d), ??6.09 (d, 2C), ??2.09 (d), 
45.42 (d) 38.?5 (q), 2?.79 (q 2C); Anal. Calcd for (C?6H20ClN5) C, 60.47; H, 6.34; N, 22.04; 
Found: C, 60.55, H, 6.52; N, 2?.96.
5-(4,5-Dihydro-?H-imidazol-2-yl)-2-(?-methyl-?H-pyrrol-2-yl)-?H-benzimidazole-5-
carboxamidine hydrochloride (6) 
From ?-methyl-?H-pyrrole-2-carbaldehyde (0.?09g, ?.0mmol), 4-(4,5-dihydro-?H-imidazol-
2-yl)-benzene-?,2-diamine (0.2?2g, ?.0mmol) and p-benzoquinone (0.?08g, ?.0mmol) in 
absolute ethanol (5ml) after refluxing for 4h yielded  0.?0?g, 33.9%, mp >290ºC. MS m/z:
266.3 (M+?, -HCl); IR (cm-?): 3390, 3094, 2976, ?606, ?582; ?H NMR (DMSO-d6) (δ /ppm): 
?3.26 (bs, ?H, NH), ?0.2 (bs, 2H, NH), 8.03 (s, ?H), 7.8?-7.78 (m, ?H), 7.75 (d, ?H, J=8.34
Hz), 7.49 (d, ?H, J=8.34 Hz), 7.46-7.43 (m, 2H), 4.?? (s, 4H, CH2), 4.0 (s, 3H, CH3) ; Anal. 
Calcd for (C?5H?6ClN5) C, 59.70; H, 5.34; N, 23.2?; Found: C, 59.73; H, 5.2?; N, 23.32.
2-Pyridin-2-yl-?H-benzimidazole-5-carboxamidine hydrochloride (7) 
From pyridine-2-carbaldehyde (0.025g, 0.23mmol), 3,4-diaminobenzamidine (0.040g, 
0.22mmol) and p-benzoquinone (0.025g, 0.23mmol) in absolute ethanol (5ml) after refluxing 
for 4h yielded  0.04?g, 65.?%, mp >290ºC. MS m/z: 238.0 (M+?, -HCl); IR (cm-?): 302?,
?629, ?595, ?560, ?535; ?H NMR (DMSO-d6) (δ /ppm): ?3.70 (bs, ?H, NH), 9.40 (bs, 4H, 
NH), 8.79 (d, ?H, J=4.4 Hz), 8.38 (d, ?H, J=7.9 Hz), 8.28 (s, ?H), 8.06 (dd, ?H, J=7.6 Hz), 
7.7?-7.58 (m, 3H) ; Anal. Calcd for (C?3H?2ClN5): C, 57.04; H, 4.42; N, 25.59; Found: C, 
56.99; H, 4.56; N 25.34. 
N-Isopropyl-2-pyridin-2-yl-?H-benzimidazole-5-carboxamidine hydrochloride (8) 
From pyridine-2-carbaldehyde (0.?07g, ?.0mmol), 3,4-diamino-N-isopropylbenzamidine 
(0.228g, ?.0mmol) and p-benzoquinone (0.?08g, ?.0mmol) in absolute ethanol (5ml) after 
refluxing for 4h yielded  0.202g, 64.?%, mp 259-26?ºC. MS m/z: 280.? (M+?, -HCl) ; ?H NMR 
(DMSO-d6) (δ /ppm): ?3.70 (bs, ?H, NH), 9.40 (bs, 4H, NH), 8.79 (d, ?H, J=4.4  Hz), 8.38 
(d, ?H, J=7.8 Hz), 8.28 (s, ?H), 8.06 (dd, ?H, J=7.8 Hz), 7.7?-7.58 (m, 3H), 4.?4 (m, ?H), 
?.30 (d, 6H, J=6.3  Hz) ; ?3C NMR (DMSO-d6) (δ /ppm): ?66.45 (s), ?50.09 (d), ?48.?4 (s), 
?43.78 (s), ?39.?? (s), ?38.3? (d), ?34.96 (s), ?23.28 (d), ?22.39 (d), ?22.25 (s), ?2?.89 (d), 
??6.09 (d), ??3.03 (d);  Anal. Calcd for (C?6H?8ClN5): C, 60.85; H, 5.75; N, 22,?8; Found: C, 
60.90; H, 5.6?; N 22.0?.
5-(4,5-Dihydro-?H-imidazol-2-yl)-2-Pyridin-2-yl-?H-benzimidazole-5-carboxamidine 
hydrochloride (9) 
From pyridine-2-carbaldehyde (0.095g, ?.0mmol), 4-(4,5-dihydro-?H-imidazol-2-yl)-
benzene-?,2-diamine (0.2?2g, ?.0mmol) and p-benzoquinone (0.?08g, ?.0mmol) in absolute 
ethanol (5ml) after refluxing for 4h yielded  0.?56g, 52.2%, mp >290ºC. MS m/z: 264.2 (M+?,
-HCl) ; IR (cm-?): 3045, 2980, ?629,?595,?560; ?H NMR (DMSO-d6) (δ /ppm): ?3.80 (bs, ?H, 
NH), ?0.6 (bs, 2H, NH), 8.79 (d, ?H, J=3.96  Hz), 8.48 (s, ?H), 8.38 (d, ?H, J=7.8  Hz), 8.06 
(dd, ?H, J=7.66 Hz), 7.93 (d, ?H, J=8.43 Hz), 7.75 (d, ?H, J=8.52 Hz), 7.60 (dd, ?H, J=6.48
Hz), 4.0? (s, 4H, CH2); Anal. Calcd for (C?5H?4ClN5) C, 60.?0; H, 4.7?; N, 23.36; Found: C, 
59.98; H, 4.80; N, 23.?5. 
Biogical Tests.  
Proliferation Assays.  
The HeLa (cervical carcinoma), MiaPaCa-2 (pancreatic carcinoma), SW 620 (colon 
carcinoma), MCF-7 (breast carcinoma), H460 (lung carcinoma), and WI 38 (normal 
fibroblasts) cells were cultured as monolayers and maintained in Dulbecco's modified Eagle 
medium (DMEM) supplemented with ?0% fetal bovine serum (FBS), 2 mM L-glutamine, ?00 
U/ml penicillin and ?00 μg/ml streptomycin in a humidified atmosphere with 5% CO2 at 37 
°C. The cell lines were inoculated onto a series of 96-well microtiter plates on day 0, at ? × 
?04 to 3 × ?04 cells/ml, depending on the doubling times of specific cell line. Test agents were 
then added in five, ?0-fold dilutions (?0-8 to ?0-4 M) and incubated for a further 72 hours. 
Working dilutions were freshly prepared on the day of testing. The solvent (DMSO) was also 
tested for eventual inhibitory activity by adjusting its concentration to be the same as in 
working concentrations. After 72 hours of incubation the cell growth rate was evaluated by 
performing the MTT assay, which detects dehydrogenase activity in viable cells, as described 
previously35, 36. The absorbance (OD, optical density) was measured on a microplate reader at 
570 nm. The percentage of growth (PG) of the cell lines was calculated according to one or 
the other of the following two expressions:
If (mean ODtest – mean ODtzero) ? 0 then 
 PG = ?00 x (mean ODtest – mean ODtzero) / (mean ODctrl – meanODtzero). 
If (mean ODtest – mean ODtzero) < 0 then: 
PG = ?00 x (mean ODtest – mean ODtzero) / ODtzero.
Where: 
Mean ODtzero = the average of optical density measurements before exposure of cells 
to the test compound. 
Mean ODtest = the average of optical density measurements after the desired period of 
time. 
Mean ODctrl = the average of optical density measurements after the desired period of 
time with no exposure of cells to the test compound. 
Each test point was performed in quadruplicate in three individual experiments. The results 
are expressed as IC50, which is the concentration necessary for 50% of inhibition. The IC50
values for each compound are calculated from dose-response curves using linear regression 
analysis by fitting the test concentrations that give PG values above and below the reference 
value (i.e. 50%). If however, for a given cell line all of the tested concentrations produce PGs 
exceeding the respective reference level of effect (e.g. PG value of 50), then the highest tested 
concentration is assigned as the default value, which is preceded by a ">" sign. Each result is 
a mean value from three separate experiments. 
Antiviral Activity Assays. 
Cell lines. HeLa (human cervical carcinoma) and GMK (green monkey kidney) cell lines 
were used. Monolayer cell cultures were grown in Dulbecco's modified Eagle medium 
(DMEM) supplemented with ?0% fetal bovine serum (FBS), 2 mM L-glutamine, ?00 U/ml 
penicillin and ?00 μg/ml streptomycin in a humidified atmosphere with 5% CO2 at 37 °C. 
Virus strains. Adenovirus 5 (ATCC VR-5) and herpesvirus ? (ATCC VR-?545) were grown 
on HeLa cells, while coxsackie B5 (ATCC VR-?85) and echovirus 7 (ATCC VR-?047) were 
grown on GMK cells in DMEM supplemented with 2% FBS, 2 mM L-glutamine, ?00 U/ml 
penicillin and ?00 μg/ml streptomycin in a humidified atmosphere with 5% CO2 at 37 °C
Antiviral assay. HeLa cells were seeded at ?05 cells/mL on 24-well microtitre plates, while 
GMK cells were seeded on 96-well microtitre plates at ?05 cells/mL. Different concentrations 
of tested compounds (serial dilution from ?0-4 to ?0-?0M) were added to one-day-old confluent 
cell monolayers that were immediately after infected with either adenovirus, herpesvirus or 
enteroviruses (coxsackievirus and echovirus) at ?0 CCID50 (? CCID50 corresponds to the 
viral stock dilution that is infective for 50% of the cell cultures) in DMEM supplemented in 
2% FS. The inhibition of the cythopathic effect (CPE) was followed by an optical microscope 
24 h after infection for enteroviruses (coxsackievirus and echovirus) and 48 h for 
adenoviruses and herpesviruses.37 Furthermore, CPE of enteroviruses (cell lysis) was 
evaluated by MTT test.38 The results were shown as the percentage of CPE inhibition 
compared to CPE without compounds on each plate and were statistically analysed on a 
personal computer. The concentration values that inhibit 50% of viral CPE (EC50) were 
calculated using the linear regression model. 
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Figure and Scheme legends 
Scheme 1. Synthesis of 2,5-substituted benzimidazoles. 
Figure 1. 2,5-substituted benzimidazole.
Figure 2. Dose-response profiles for compounds 6  and 9 tested on various human cell lines in 
vitro. The cells were treated with the compounds at different concentrations, and the 
percentage of growth (PG) was calculated. Each point represents a mean value of four parallel 
samples in three individual experiments. 
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Figure 2. 
Table 1. In vitro inhibition of the growth of tumor cell lines and normal human fibroblasts 
(WI 38).  
IC50
a (μM) 
Compd. 
H 460 HeLa  MiaPaCa-2 SW 620  MCF-7 WI 38 
1 >100 >100 34±49 >100 7,2±3 >100 
2 >100 >100 >100 >100 26±26 >100 
3 >100 >100 >100 >100 ?100 >100 
4 >100 70±27 >100 84±3 12±3 >100 
5 >100 >100 >100 >100 20±8 >100 
6 38±7 20±0,9 11.5±0,1 15±2 5±1 15,6±1,9 
7 >100 82±17 >100 >100 ?100 59,4±42,7 
8 >100 >100 79±18 >100 50±23 20.4±9.9 
9 22.5±1,4 16±0,8 16±0,2 19±0,6 12±6 12±2 
Cis  b 0,3±0,04 2,9±0,6 5,4±1,6 4±1,8 12±6 19±20 
Eto b 0,2±0,1 2,9±1 15,4±14 20±3,4 50±30 N.T. c
a IC50; the concentration that causes a 50% reduction of the cell growth; b Cis – cisplatin, Eto – 
etoposide; c N.T. – not tested 
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Table 2. In vitro inhibition of the growth on respective cell lines of adenovirus 5, herpesvirus 
1, coxsackievirus B5 and echovirus 7.  
Antiviral activity EC50
 a
 (μM) 
Compd. HeLa GMK 
 Adenovirus 5 Herpesvirus 1 Coxsackievirus B5 Echovirus 7 
1 N.A. b N.A. >100 >100
2 N.A. >100 >100 >100
3 N.A. >100 >100 >100
4 5,9±10 30±14,1 3,5±4,9 5±3,2 
5 N.A. N.A. >100 23,2±32,1 
6 >100 28,5±30,4 >100 >100
7 >100 >100 1,7±1,6 3,2±3,3 
8 15,2±31,4 >100 2,7±4,6 0,33±0,21 
9 >100 56,7±61,3 4,3±3,1 0,63±0,38 
a EC50 represents the drug concentration that causes inhibition of viral growth by 50%; given values 
are means of at least tree independent optical evaluation of CPE for adenovirus 5 and herpesvirus 1 
grown on HeLa cell lines and at least two independent MTT experiments for coxsackievirus B5 and 
echovirus 7 grown on GMK cell lines; b N.A. no antiviral activity determined.   
